Рет қаралды 406
In this video, Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, comments on the important role of TP53 in chronic lymphocytic leukemia (CLL), emphasizing its function as a tumor suppressor gene. Dr Rosenquist also explains how TP53 aberrations play a role in patient response to therapy and the growing importance of BTK inhibitors and BCL2 inhibitors as a treatment option for these patients. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
Explore our dedicated feature on genomic testing in CLL here: bit.ly/403y417
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.